Daylight photodynamic therapy for prevention of new actinic keratosis and keratinocyte carcinomas in organ transplants. A cryotherapy‐controlled randomized clinical trial

Background Organ transplant recipients (OTR) have a higher risk of actinic keratosis (AK) and keratinocyte carcinomas (KC). There are no clinical trials assessing the effectiveness of daylight photodynamic therapy (DPDT) to prevent new AK and KC in OTR. Objectives To determine whether repeated treat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2020-07, Vol.34 (7), p.1464-1470
Main Authors: Bernad, I., Aguado, L., Núñez‐Córdoba, J.M., Redondo, P.
Format: Article
Language:English
Subjects:
Aged
Aminolevulinic Acid - therapeutic use
Carcinoma
Cryotherapy
Humans
Keratinocytes
Keratosis, Actinic - drug therapy
Keratosis, Actinic - prevention & control
Male
Middle Aged
Organ Transplantation
Photochemotherapy
Photosensitizing Agents - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Organ transplant recipients (OTR) have a higher risk of actinic keratosis (AK) and keratinocyte carcinomas (KC). There are no clinical trials assessing the effectiveness of daylight photodynamic therapy (DPDT) to prevent new AK and KC in OTR. Objectives To determine whether repeated treatments of field cancerization with DPDT are effective in preventing new AK and KC in OTR. Methods A randomized, intra‐subject controlled, evaluator‐blind, split‐face and/or scalp trial, from April 2016 to October 2018. Participants were OTR older than 18 years, 1‐year posttransplant, with at least 5 AK on each hemi‐face/hemi‐scalp. One side received six field treatments with DPDT: two sessions 15 days apart at baseline, two at 3 months and two at 9 months after baseline. Control side received lesion‐directed treatment with cryotherapy (double freeze–thaw) at baseline, 3 and 9 months. Total number of lesions (AK and KC) at 21 months, number of new AK and KC at 3, 9, 15 and 21 months and treatment preferences were analysed. Results Of 24 men included, 23 were analysed at 3 months; and 21, at 9, 15 and 21 months. Mean (SD) age was 69.8 years (9.2). The total number of lesions at 21 months was 4.7 (4.3) for DPDT and 5.8 (5.0) for control side; P = 0.09. DPDT showed significantly lower means [SD] of new lesions compared to control side at 3 months (4.2 [3.4] vs. 6.8 [4.8]; P 
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.16125